Blood pressure (BP) control is considered the most important treatment for preventing chronic kidney disease (CKD) progression and associated cardiovascular complications. However, clinic BP is insufficient to diagnose hypertension (HT) and to monitor overall BP control because it does not correlate well with ambulatory blood pressure monitoring (ABPM). We enrolled 387 hypertensive CKD patients (stages G1-G4, 58.4% male with median age 61 years) from 3 hospitals in Korea. HT of clinic BP and ABPM was classified as ≥140/90 and ≥130/80 mmHg, respectively. Clinic BP control rate was 60.2%. The median 24-hour systolic blood pressures (SBPs) of CKD G3b and CKD G4 were significantly higher than those of CKD G1-2 and CKD G3a. However, the median 24-hour SBPs were not different between CKD G1-2 and CKD G3a or between CKD G3b and CKD G4. Of all patients, 5.7%, 38.0%. 42.3%, and 14.0% were extreme-dippers, dippers, non-dippers, and reverse-dippers, respectively. Non-/reverse-dippers independently correlated with higher Ca × P product, higher intact parathyroid hormone (iPTH), and lower albumin. Normal BP was 33.3%, and sustained, masked, and white-coat HT were 29.7%, 26.9%, and 10.1%, respectively. White-coat HT independently correlated with age ≥61 years and masked HT independently correlated with CKD G3b/G4. In conclusion, ABPM revealed a high prevalence of non-/reverse-dippers and sustained/masked HT in Korean CKD patients. Clinicians should try to obtain a CKD patient's ABPM, especially among those who are older or who have advanced CKD as well as those with abnormal Ca × P product, iPTH, and albumin.
INTRODUCTION
Chronic kidney disease (CKD) is a major health problem, and it affects -10% of adults in Western countries (1) . In Korea, CKD prevalence was 7.8% overall (Korea National Health and Nutri tion Examination Survey [KNHANES] data) and 13.7% in urban population with age ≥ 35 years in Korea (2, 3) . Among various risk factors, hypertension (HT) is considered an important one in the development and progression of CKD (4) . HT also incre ases the risk of death and cardiovascular disease (5) .
To reduce these risks, recent guidelines recommend strict con trol of blood pressure (BP) to ≤ 130/80 and ≤ 140/90 mmHg in CKD patients with and without proteinuria, respectively (4, 6) . However, a large proportion of CKD patients have inadequate BP control, and the proportions vary from report to report (7, 8) . Furthermore, BP may not be properly controlled in many Kore an CKD patients. In Korea, KNHANES guidelines suggested that 58.5% of the general population had appropriate clinic BP (< 130/ 80 mmHg), and an Assessment of Blood Pressure Control and Target Organ Damage in Patients with Chronic Kidney Disease and Hypertension (APrODiTe) study reported that 53.4% of CKD patients had controlled clinic BP ( < 140/90 mmHg) (9, 10) . Fur thermore, it is important to increase the BP control rate as kid ney function deteriorates. The National Kidney FoundationKid ney Early Evaluation Program (NKFKEEP) in the United States reported that rates of HT awareness, treatment, and adequate HT control increased progressively with advancing kidney dis ease despite increasing HT prevalence (11) . Unfortunately, this aspect of BP control is not known in Korean CKD patients.
Clinic BP is considered insufficient to diagnose HT and mon itor overall BP control because it does not correlate well with ambulatory blood pressure monitoring (ABPM), which encom passes whitecoat or masked HT (12, 13) . CKD is associated not only with an abnormal dipping pattern but also with whitecoat or masked HT (7, 10, 1419) . These abnormal ABPM patterns are considered to be associated with cardiovascular disease and CKD progression (20) .
We conducted a multicenter, crosssectional study to exam ine BP control status and patterns and dipping patterns in Ko rean CKD patients. We also investigated clinical characteristics
MATERIALS AND METHODS

Study population
From August 2014 to May 2015, patients with HT and CKD stag es G1-G4 treated at the Seoul National University Boramae Med ical Center, Seoul National University Hospital, and Seoul Na tional University Bundang Hospital were enrolled. The inclu sion criteria were as follows: 1) age of 20-75 years, 2) BP ≥ 140/ 90 mmHg, and/or 3) taking the same BP medication since at least 2 weeks before enrollment. Patients with acute kidney in jury, hospitalization, renal replacement therapy, previous kid ney transplantation, uncontrolled arrhythmia, asthma, chronic obstructive pulmonary disease, and primary endocrine disor ders except diabetes mellitus were excluded. Pregnant women and anyone who worked night shifts were also excluded.
Definitions
CKD is defined by the Kidney Disease Improving Global Out comes (KDIGO) as abnormalities of kidney structure or func tion that are present for at least 3 months (4). CKD stages were defined according to glomerular filtration rate (GFR) categories as defined by KDIGO guidelines (4). The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney DiseaseEpidemiology Collaboration equation (21) . Serum cre atinine (Cr) was measured using the isotope dilution mass spec trometrytraceable method. Extremedippers were defined as patients having a nighttime/daytime systolic blood pressure (SBP) ≤ 0.8; dippers, as those with a ratio of 0.8-0.9; nondip pers, as those with a ratio of 0.9-1.0; and reversedippers, as those with a ratio > 1.0 (22) . HT as diagnosed by clinic BP and ABPM measurements was ≥ 140/90 and ≥ 130/80 mmHg, respective ly. Normal BP was defined as both normal clinic BP and ABPM; sustained HT, as both HT clinic BP and ABPM; whitecoat HT, as a HT clinic BP and normal ABPM (12) ; and masked HT, as normal clinic BP and HT ABPM (13) .
Clinic BP measurement
Clinic BP was measured by trained medical staff using a mer cury sphygmomanometer with an appropriately sized cuff (23) . All participants rested over 5 minutes and were prohibited from smoking and ingesting caffeine for 30 minutes before measure ments. Three measurements were performed at 1minute in tervals, and the average of the last 2 measurements was taken as the clinic BP.
ABPM
Patients underwent 24hour ABPM using Oscar 2 (SunTech Med ical, Morrisville, NC, USA) and MobileOGraph (I.E.M. GmbH, Stolberg, Germany). BP monitoring was performed on a typical work day. BP was recorded every 30 minutes. The ABP reading was considered adequate if the monitor had been worn for 24 hour and there were more than 16 acceptable readings between 8 AM and 10 PM (daytime) and more than 12 acceptable read ings between 10 PM and 8 AM (nighttime).
Baseline demographics and clinical characteristics
Demographic characteristics, CKD causes, medical history, and laboratory data such as hemoglobin (Hb), albumin, blood urea nitrogen (BUN), Cr, calcium (Ca), phosphorus (P), intact para thyroid hormone (iPTH), total cholesterol (TotalC), highden sity lipoprotein cholesterol (HDLC), lowdensity lipoprotein cholesterol (LDLC), triglycerides (TG), and random urine pro tein/Cr ratio (UPCR) were obtained at the baseline study visit. Comorbidities were evaluated using the modified Charlson Co morbidity Index Score (CCIS) (24) .
Statistical analysis
Quantitative variables are presented as mean ± standard devia tion (SD) for normally distributed variables. Nonparametric variables are expressed as median (range). Categorical variables are expressed as numbers with proportions. Quantitative vari ables were analyzed using analysis of variance (ANOVA) followed by the Bonferroni posthoc test or the KruskalWallis or Mann Whitney rank sum tests for nonparametric variables. Chisquare tests were used to compare categorical variables. Simple logis tic regression analysis was applied to find the unadjusted fac tors that correlated with dipping patterns and BP control pat terns. Multiple logistic regression analysis with backward elimi nation technique adjusted for factors with P < 0.05 was used to identify independent predictors of dipping patterns and BP con trol patterns. The relationship between the 2 continuous vari ables was assessed by Pearson's correlation method. Statistical analysis was performed using IBM SPSS Statistics 20 (SPSS Inc., Chicago, IL, USA). P value < 0.05 was considered statistically significant.
Ethics statement
The present study protocol was reviewed and approved by the Institutional Review Board of Seoul National University Bora mae Medical Center (26201463), Seoul National University Hospital (1406131593), and Seoul National University Bun dang Hospital (B1408/262403). Informed consent was sub mitted by all subjects when they were enrolled.
RESULTS
A total of 433 patients agreed to undergo ABPM, and 46 patients were excluded because they withdrew from the study or their ABPM measurements were not adequate. Finally, 387 CKD pa tients were enrolled in this study (Fig. 1) . Values for categorical variables are given as a number (%); Values for continuous variables are given as mean ± standard deviation or median (range). ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker, BMI = body mass index, BUN = blood urea nitrogen, Ca = calcium, CCB = calcium channel blocker, CCIS = modified Charlson Comorbidity Index Score, CKD = chronic kidney disease, Cr = creatinine, eGFR = estimated glomerular filtration rate, Hb = hemoglobin, HDL-C = high-density lipoprotein cholesterol, iPTH = intact parathyroid hormone, LDL-C = low-density lipoprotein cholesterol, No. = number, P = phosphorus, TG = triglyceride, Total-C = total cholesterol, UPCR = random urine protein/creatinine ratio. C D E a higher proportion of CKD G3b/G4, but no statistically signifi cant difference. Reversedippers showed higher median P (P = 0.001), TG (P = 0.020), and nighttime SBP (P < 0.001) and lower median albumin (P < 0.001) than extremedippers, dippers, and nondippers. They also showed higher median UPCR than ex tremedippers and dippers (P = 0.028). Reversedippers showed https://doi.org/10.3346/jkms.2017.32.5.772
higher mean Ca × P product than dippers and nondippers (P < 0.001) ( Table 2 ). The Ca × P product and iPTH positively correlated with night time/daytime SBP ratio (R 2 = 0.033, P < 0.001 and R 2 = 0.017, P = 0.011, respectively) (Fig. 3) . The P, Ca × P product, iPTH, al bumin, nighttime SBP, and nighttime DBP significantly corre lated with the non/reversedippers in univariate analyses. Mul tiple logistic regression analyses conducted with the above fac tors and eGFR showed that the Ca × P product (odds ratio [OR], 1.212; 95% confidence interval [CI], 1.041-1.411; P = 0.013), iPTH (OR, 1.008; 95% CI, 1.002-1.014; P = 0.013), and albumin (OR, 0.363; 95% CI, 0.174-0.761; P = 0.007) were independently as sociated with non/reversedippers when BP data were not in cluded. When multiple logistic regression analyses were per formed with the above factors, eGFR, and BP data, the Ca × P product (OR, 1.247; 95% CI, 1.053-1.582; P = 0.011), nighttime SBP (OR, 1.042; 95% CI, 1.022-1.062; P < 0.001), and nighttime DBP (OR, 1.040; 95% CI, 1.010-1.070; P = 0.008) were indepen dently associated with non/reversedippers (Table 3) .
BP control patterns
Among all patients, normal BP was most common (33.3%), fol lowed by sustained HT (29.7%), masked HT (26.9%), and white coat HT (10.1%). The median 24hour SBP (P < 0.001), daytime SBP (P < 0.001), and nighttime SBP (P < 0.001) were the highest in sustained HT than in normal BP, whitecoat HT, and masked HT. Masked HT showed higher ABPM SBPs than normal BP and whitecoat HT (P < 0.001) (Table 4) . However, clinic SBP was Values for categorical variables are given as a number (%); Values for continuous variables are given as mean ± standard deviation or median (range). ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker, BMI = body mass index, BP = blood pressure, BUN = blood urea nitrogen, Ca = calcium, CCB = calcium channel blocker, CCIS = modified Charlson Comorbidity Index Score, CKD = chronic kidney disease, Cr = creatinine, DBP = diastolic blood pressure, eGFR = estimated glomerular filtration rate, Hb = hemoglobin, HDL-C = high-density lipoprotein cholesterol, iPTH = intact parathyroid hormone, LDL-C = low-density lipoprotein cholesterol, No. = number, P = phosphorus, SBP = systolic blood pressure, TG = triglyceride, Total-C = total cholesterol, UPCR = random urine protein/creatinine ratio. not different between sustained HT and whitecoat HT (Table 4) . Normal BP showed lower median BUN (P < 0.001), Cr (P < 0.001), and CCIS (P = 0.003); higher median eGFR (P < 0.001) and HDLC (P = 0.007); and lower proportion of DM (P < 0.001) and CKD G3b/G4 (P < 0.001) than sustained HT, whitecoat HT, and masked HT. Normal BP also showed lower median iPTH (P = 0.002) and UPCR (P = 0.001) than sustained HT and masked HT. Sustained HT showed a higher proportion of DM (P < 0.001) and lower proportion of CKD G3b/G4 (P < 0.001) than masked HT. Sustained HT and masked HT showed lower median albu min (P = 0.002) than normal BP and whitecoat HT. Sustained and masked HT patients were also prescribed more diuretics than those with normal BP (P = 0.009) ( Table 4) .
Multiple logistic regression analyses showed that age ≥ 61 years (OR, 0.601; 95% CI, 0.378-0.957; P = 0.032), Cr (OR, 0.352; 95% CI, 0.237-0.523; P < 0.001), and HDLC (OR, 1.015; 95% CI, 1.002-1.928; P = 0.012) independently associated with normal BP. DM (OR, 1.921; 95% CI, 1.170-3.154; P = 0.010), Ca (OR, 0.585; 95% CI, 0.348-0.980; P = 0.042), and LDLC (OR, 1.007; 95% CI, 1.000-1.014; P = 0.037) independently associated with sustained HT. Age ≥ 61 years (OR, 2.117; 95% CI, 1.035-4.331; P = 0.040) independently correlated with whitecoat HT. CKD G3b/G4 (OR, 2.778; 95% CI, 1.695-4.552; P < 0.001) independently correlated with masked HT (Table 5) .
DISCUSSION
This study demonstrated that the clinic BP control rate was 60.2%. The median 24hour SBPs of CKD G3b and CKD G4 were sig nificantly higher than those of CKD G1-2 and CKD G3a. How ever, the median 24hour SBPs were not different between CKD G1-2 and CKD G3a or between CKD G3b and CKD G4. Of all Korean CKD patients, 56.3% were non/reversedippers. Non/ reversedippers are associated with higher P, higher Ca × P prod uct, and lower albumin. They also show high prevalence of sus tained HT (29.7%) and masked HT (26.9%). Sustained HT cor related with DM, lower Ca, and higher LDLC. Whitecoat HT was associated with age ≥ 61 years and masked HT was associ ated with CKD G3b/G4.
Many previous studies have reported on control of clinic BP in CKD patients. NKFKEEP showed that 31.4% and 13.2% of patients maintained clinic BP ≤ 140/90 and 130/80 mmHg, re Model 1: adjusted for P, Ca × P, iPTH, albumin, eGFR, and UPCR; Model 2: adjusted for P, Ca × P, iPTH, albumin, eGFR, UPCR, nighttime SBP, and nighttime DBP. Ca = calcium, CI = confidence interval, DBP = diastolic blood pressure, eGFR = estimated glomerular filtration rate, iPTH = intact parathyroid hormone, OR = odds ratio, P = phosphorus, SBP = systolic blood pressure, UPCR = random urine protein/creatinine ratio.
https://doi.org/10.3346/jkms.2017.32.5.772 .7) 75 (72.1) < 0.001 Ca, mg/dL 9.1 (7.6-10.1) 8.9 (7.6-9.9)* , § 9.1 (7.9-9.9) 9.1 (7. spectively (11) . Among Chronic Renal Insufficiency Cohort (CRIC) Study participants, 67.1% and 46.1% showed clinic BP control rates of < 140/90 and < 130/80 mmHg, respectively (8) . However, at Spanish ABPM Registry report showed that only 21.7% and 9.1% of CKD patients maintained clinic BP < 140/90 and < 130/80 mmHg, respectively (7) . In Korea, the APrODiTe study reported that 53.4% of CKD patients had controlled clinic BP ( < 140/90 mmHg) (10) . This study showed a similar controlled clinic BP rate (60.2%). Previous studies demonstrated that controlled BP rates in creased with CKD progression. NKFKEEP reported that rates of HT awareness, treatment and adequate HT control increased with advancing kidney disease despite increasing prevalence of HT (11) . The Spanish ABPM Registry analysis also showed that BP control trends from no CKD to CKD stage 5 increased pro gressively for BP maintenance at the < 130/80 mmHg thresh old. They also reported that 24hour BP control did not change from no CKD to CKD stage 5 (7). In contrast, Wu et al. (25) re ported that 24hour, daytime, and nighttime SBPs and DPBs were higher in CKD stages 4-5 than CKD stages 1-3. This study demonstrated that clinic SBP was higher in CKD G4 than in oth er groups. In the case of ABPM, CKD G3b/G4 showed higher 24hour, daytime, and nighttime SBPs than CKD G1-2/G3a. The ABPM SBPs were not different between CKD G1-2 and CKD G3a or between CKD G3b and CKD G4. Most CKD studies that examined the association between complications and CKD stag es were based on the previous 5 stages (26 Normal BP: adjusted for sex, age ≥ 61 years, Diabetes mellitus, CCIS, BUN, Cr, eGFR, CKD G3b/G4, Ca, P, iPTH, UPCR ≥ 1 mg/mg, HDL-C, Hb, albumin, and diuretics; Sustained HT: adujusted for DM, CCIS, Cr, eGFR, Ca, iPTH, UPCR ≥ 1 mg/mg, LDL-C, albumin, and diuretics; White-coat HT: adjusted for age ≥ 61 years, Total-C, and HDL-C; Masked HT: adujusted for CCIS, BUN, Cr, eGFR, CKD G3b/4, and UPCR ≥ 1 mg/mg. BP = blood pressure, BUN = blood urea nitrogen, Ca = calcium, CCIS = modified Charlson Comorbidity Index Score, CKD = chronic kidney disease, CI = confidence interval, Cr = creatinine, eGFR = estimated glomerular filtration rate, Hb = hemoglobin, HDL-C = high-density lipoprotein cholesterol, HT = hypertension, iPTH = intact parathyroid hormone, LDL-C = low-density lipoprotein cholesterol, OR = odds ratio, P = phosphorus, Total-C = total cholesterol, UPCR = random urine protein/creatinine ratio.
ferent outcomes and risk profiles into categories G3a (eGFR 45-59 mL/min/1.73 mg 2 ) and G3b (eGFR 45-59 mL/min/1.73 mg 2 ) (4). This study showed that outcomes and risk profiles as well as BP control patterns, were different between CKD G1-2/G3a and CKD G3b/G4. These results suggest that careful BP moni toring and treatment are essential from the moment CKD pa tients reach CKD G3b.
Non/reversedipping indicate that nighttime BP did not de crease or was even higher than daytime BP. As non/reverse dipping is considered a risk factor of cardiovascular events in nonCKD hypertensive patients, non/reversedipping is con sidered a risk factor of CKD progression (27, 28) . Non/reverse dipping was also shown to be a risk factor for cardiovascular events and correlated with markers for cardiovascular events in CKD patients (10, 1416, 28, 29) . Multiple factors cause suppressed nighttime BP decrease, such as older age, race, autonomic dys function, abnormal sleepwake cycle, and sodium sensitivity (30) . In addition, Feldstein et al. (31) reported that nondippers were associated with elevated serum Ca in elderly essential hy pertensive patients with mildtomoderate CKD, and Kanbay et al. (32) reported that the nondipper clinical profile is related to serum Ca, P, and PTH in hypertensive patients with normal re nal function. In this study, the nighttime/daytime SBP ratio cor related significantly with the Ca × P product and iPTH. We also suggested that the Ca × P product, iPTH, and albumin were in dependently associated with non/reversedippers in a multi ple logistic regression model even after adjusting for eGFR. In particular, the Ca × P product independently correlated with non/reversedippers after adjusting for nighttime SBP and DBP. Elevated serum P and Ca × P product were associated with poor outcomes according to the International Dialysis Outcomes Practice Patterns Study and a cohort from The Netherlands that included both hemodialysis and peritoneal dialysis patients (33, 34) . Serum Ca, P, and PTH are factors that promote vascular calcification (35) . Increased serum P also stimulates fibroblast growth factor23 (FGF23) and PTH secretion. Elevated FGF23 levels appear to be associated with poor clinical outcomes (35) . However, because FGF23 is not yet routinely measured in gen eral clinical practice, a clinician should estimate CKDmineral bone disorders using parameters that can be measured easily. The results of this study suggested that abnormal Ca, P, and PTH, all of which reflect abnormal mineral metabolism, vascular cal cification, and poor outcome, could predict increased nighttime BP and non/reversedipping.
The high prevalence of whitecoat and masked HT in patients with CKD support the need to measure outofoffice BP, such as ABPM or home BP to confirm that a patient's BP is under con trol. In this study, the prevalence of whitecoat and masked HT was 10.1% and 26.9%, respectively. These results were similar to those of the African American Study of Kidney Disease Cohort study (2.2% and 42.9%, respectively), CKD Japan cohort (5.6% and 30.9%, respectively), APrODiTe study (4.3% and 33.9%, re spectively), and CRIC Study (4.1% and 27.8%, respectively) (10, 14, 18, 19) . However, the prevalence of whitecoat HT and masked HT was respectively 18.3% and 8.3% in metaanalysis by Ban gash and Agarwal and 28.8% and 7.0% in the Spanish ABPM Registry, suggesting that their prevalence was respectively ≥ 15% and ≤ 10% (7, 17) . The differences in the prevalence of BP con trol type are attributable to race, ethnicity, and renal function in addition to diagnostic thresholds.
Previous studies of CKD cohorts showed that masked HT was associated with low eGFR, elevated urine protein excretion, high er left ventricular hypertrophy and higher pulse wave velocity (10, 14, 18, 19) . In this study, masked HT was associated with low er eGFR, higher prevalence of CKD G3b/G4, and elevated UPCR than patients with normal BP. These data indicate that masked HT patients appear to have decreased renal function and ele vated proteinuria. Therefore, clinician should carefully monitor outofoffice BP in CKD patients.
This study has several limitations. First, this was a crosssec tional and observational study, and therefore, it has limitations in establishing a causeeffect relationship. Second, important parameters such as FGF23, echocardiography, and pulse wave velocity, were not obtained; this further limits the clarification of causality. Third, because ABPM was evaluated only once, vari ability in measurements was not considered. This might result in some degree of misclassification. Finally, because this study had a small number of participants, its statistical power was not high enough for some parameters.
In conclusion, the median ABPM SBPs of CKD G3b and CKD G4 were significantly higher than those of CKD G1-2 and CKD https://doi.org/10.3346/jkms.2017.32.5.772
G3a. ABPM showed a high prevalence of non/reversedippers and sustained/masked HT. Non/reversedippers correlated with higher Ca × P product, higher iPTH, and lower albumin. Whitecoat HT correlated with old age and sustained HT, with advanced CKD. Clinicians should attempt to perform ABPM in CKD patients, especially in those who are older or have advanced CKD as well as those who have abnormal Ca × P product, iPTH, and albumin.
